Predictive value of baseline electronic columbia–suicide severity rating scale (Ec–ssrs) assessments for identifying risk of prospective reports of suicidal behavior during research participation

Innovations in Clinical Neuroscience

Volumn 11, Issue 9-10, 2014, Pages 23-31

  Greist, John H ^a   Mundt, James C ^b   Gwaltney, Chad J ^c   Jefferson, James W ^a   Posner, Kelly ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Center for Telepsychology   (United States)

^c Department of Pharmacy at Thomas Jeff erson   (United States)

^d College of Physicians and Surgeons and New York State Psychiatric Institute ^*  (United States)

Author keywords

eC SSRS; Electronic patientreported outcomes; Prospective risk; Suicide risk assessment

Indexed keywords

ARTICLE; BEHAVIOR ASSESSMENT; COLUMBIA SUICIDE SEVERITY RATING SCALE; DISEASE ASSESSMENT; DISEASE SEVERITY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MENTAL DISEASE; META ANALYSIS; PATIENT SAFETY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PSYCHIATRIC DIAGNOSIS; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION;

EID: 84938058738     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Singhal A, Ross J, Seinog O, et al. Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. J R Soc Med. 2014;107(5):194–204.
2. Luoma JB, Martin CE, Pearson H. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry. 2002;159(6):909–916.
3. Kobak KA, Brown B, Sharp I, et al. Sources of unreliability in depression ratings. J Clin Psychopharmacol. 2009;29(1):82–85.
4. Kobak KA, Lipsitz J, Williams JB, et al. Are the effects of rater training sustainable: results from a multicenter clinical trial. IJ Coin Psychopharmacol. 2007;27:534–535.
5. Gould MS, Marrocco FA, Kleinman M, et al. Evaluating iatrogenic risk of your suicide screening programs: a randomized controlled trial. JAMA. 2005;293(13):1635–1643.
6. Chappell P, Mahableshwarkar AR, Alphs, L, et al. ISCTM Suicidal Ideation and Behavior Assessment Workgroup. Prospective assessment of suicidal ideation and behavior: an internet survey of pharmaceutical sponsor practices. Innov Clin Neurosci. 2014;11(9 –10):14–22.
7. Marks I. Fears, Phobias, and Rituals: Panic, Anxiety, and their Disorders. New York: Oxford University Press; 1987:135.
8. Greist JH, Gustafson DH, Stauss FF, et al. A computer interview for suicide-risk prediction. Am J Psychiatry. 1973;130:1327–1332.
9. Hesdorffer DC, French JA, Posner K, et al. Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials. Epilepsia. 2013;54(5):879–887.
10. Levine S, Ancil RJ, Roberst AP. Assessment of suicide risk by computer delivered self-rating questionnaire: preliminary findings. Acta Psychiatr Scand. 1989;80(3):216–220.
11. Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011;72(6):757–64.
12. Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). J Clin Psychiatry. 2009;70(5):741–7.
13. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277.
14. Mundt JC, Greist JH, Gelenberg AJ, et al. Feasibility and validation of a computer-automated Columbia- Suicide Severity Rating Scale using interactive voice response technology. J Psychiatr Res. 2010;44(16):1224–1228.
15. United States Food and Drug Administration, United States Department of Health and Human Services. Guidance for Industry: Suicidality: Prospective Assessment of Occurrence inClinical Trials, Draft Guidance. September 2010. https://www.federalregister.gov/articles/2010/09/09/2010-22404/draftguidance-for-industry-onsuicidality-prospective-assessmentof-occurrence-in-clinical-trials. Accessed October 1, 2014.
16. United States Food and Drug Administration, United States Department of Health and Human Services. Guidance for Industry: Suicidality: Prospective Assessment of Occurrence in Clinical Trials, Draft Guidance. August 2012. Revision 1. http://www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf. Accessed October 1, 2014.
17. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009; 339:b2880. doi: 10.1136/bmj.b2880.
18. Beck AT, Brown GK, Steer RA, et al. Suicide ideation at its worst point: a predictor of eventual suicide in psychiatric outpatients. Suicide Life Threat Behav. 1999;29(1):1–9.
19. Brown GK, Beck AT, Steer RA, et al. Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol. 2000;68(3):371–377.
20. Mundt JC, Greist JH, Jefferson JW, et al. Prediction of suicidal behavior in clinical research by lifetime suicidal ideation and behavior ascertained by the electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry. 2013;74(9):887–893.